Q-omics provides the consensus-scored ZFP91-CNTF profile across patient tissues and cancer cell-line models. ZFP91-CNTF expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZFP91-CNTF is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, ZFP91-CNTF RNA expression shows 10,629 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where ZFP91-CNTF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP91-CNTF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP91-CNTF survival associations across molecular data types. ZFP91-CNTF RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP91-CNTF RNA expression–survival associations across cancer types. High ZFP91-CNTF expression shows unfavorable associations in MESO, ACC, KICH and ESCA, but favorable associations in COAD and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for ZFP91-CNTF RNA expression.
This table summarizes ZFP91-CNTF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZFP91-CNTF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP91-CNTF shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, LIHC, STAD and BRCA. The HNSC box plot shows higher ZFP91-CNTF RNA expression in tumor versus normal tissue (log2 FC = +0.072, t-test p < 0.001).
This table shows molecular features associated with ZFP91-CNTF in patient tissues and cancer cell lines. In patient samples, ZFP91-CNTF shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP91-CNTF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
